Modeling Endometrial Cancer: Past, Present, and Future
AbstractEndometrial cancer is the most common type of cancer of the female reproductive tract. Although prognosis is generally good for patients with low-grade and early-stage diseases, the outcomes for high-grade and metastatic/recurrent cases remain poor, since traditional chemotherapy regimens based on platinum and taxanes have limited effects. No targeted agents have been approved so far, although several new drugs have been tested without striking results in clinical trials. Over the last decades, many efforts have been made towards the establishment and development of preclinical models, aiming at recapitulating the structural and molecular determinants of the disease. Here, we present an overview of the most commonly used in vitro and in vivo models and discuss their peculiar features, describing their main applications and the value in the advancement of both fundamental and translational endometrial cancer research. View Full-Text
Share & Cite This Article
Van Nyen, T.; Moiola, C.P.; Colas, E.; Annibali, D.; Amant, F. Modeling Endometrial Cancer: Past, Present, and Future. Int. J. Mol. Sci. 2018, 19, 2348.
Van Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling Endometrial Cancer: Past, Present, and Future. International Journal of Molecular Sciences. 2018; 19(8):2348.Chicago/Turabian Style
Van Nyen, Tom; Moiola, Cristian P.; Colas, Eva; Annibali, Daniela; Amant, Frédéric. 2018. "Modeling Endometrial Cancer: Past, Present, and Future." Int. J. Mol. Sci. 19, no. 8: 2348.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.